The Saudi FDA has announced the cancellation of Alupent® 10mg L 5 mo syrup ( orciprenaline sulphate) registration due to its hazards on heart and the availability of more safe alternative drugs.
Accordingly, drug products and manufacturers' registration committee decided to cancel registration of this product and recall it from the market. SFDA also asked the manufacturer to recall any available stocks from the local market to protect the health of the public. SFDA requests all the concerned to use other alternative drugs for patients who are currently using the said product.
For further information on drug updates, please visit our drug site on SFDA website on t he following link: www.sfda.gov.sa/ar/drug
Saudi FDA Cancels the Registration of Aupent Product
إقرأ أيضا
2024-12-17
SFDA CEO Inaugurates the 3rd Meeting of the OIC Heads of National Medicines ...
The Kingdom of Saudi Arabia, represented by the Saudi Food and Drug Authority (SFDA), hosted the third meeting of the He ...
2024-12-16
SFDA Achieves Significant Milestone Receiving the National EA Certificate f ...
The Saudi Food and Drug Authority (SFDA) has obtained the National Enterprise Architecture Accreditation Certificate fro ...
2024-12-15
Clone of Saudi Arabia Hosts the 3rd Meeting of the OIC Heads of National Me ...
The Kingdom of Saudi Arabia, represented by the Saudi Food and Drug Authority (SFDA), in collaboration with the Organiza ...
2024-12-15
Saudi Arabia Hosts the 3rd Meeting of the OIC Heads of National Medicines R ...
The Kingdom of Saudi Arabia, represented by the Saudi Food and Drug Authority (SFDA), in collaboration with the Organiza ...